Prudential PLC Lowers Stock Holdings in Revvity Inc. $RVTY

Key Points

• Prudential PLC has reduced its stake in Revvity Inc. by 17.7%, holding 17,552 shares valued at approximately $1.86 million.
• Revvity recently announced a quarterly dividend of $0.07 per share, yielding 0.3%, with payment scheduled for November 7th.
• Analysts have set new price targets for Revvity, with estimates ranging from $102.00 to $125.00 following recent adjustments.

Prudential PLC lessened its stake in Revvity Inc. (NYSE:RVTY - Free Report) by 17.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,552 shares of the company's stock after selling 3,771 shares during the quarter. Prudential PLC's holdings in Revvity were worth $1,857,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the company. Optiver Holding B.V. bought a new stake in shares of Revvity during the 4th quarter valued at about $33,000. Quarry LP grew its position in Revvity by 45.7% during the fourth quarter. Quarry LP now owns 303 shares of the company's stock valued at $34,000 after buying an additional 95 shares during the period. Vermillion Wealth Management Inc. purchased a new stake in Revvity during the fourth quarter valued at approximately $41,000. New Age Alpha Advisors LLC purchased a new position in shares of Revvity during the 1st quarter worth $44,000. Finally, Continuum Advisory LLC grew its position in shares of Revvity by 39.3% during the 4th quarter. Continuum Advisory LLC now owns 471 shares of the company's stock valued at $53,000 after acquiring an additional 133 shares during the period. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Stock Up 1.8%

RVTY stock traded up $1.5750 during trading on Tuesday, reaching $91.2650. 310,995 shares of the company traded hands, compared to its average volume of 1,180,188. The business has a 50 day simple moving average of $94.87 and a 200 day simple moving average of $99.60. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.75 and a current ratio of 3.33. Revvity Inc. has a 12 month low of $85.12 and a 12 month high of $129.50. The company has a market capitalization of $10.59 billion, a price-to-earnings ratio of 38.67, a price-to-earnings-growth ratio of 2.44 and a beta of 0.91.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.04. The firm had revenue of $720.28 million for the quarter, compared to the consensus estimate of $711.26 million. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The firm's revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.22 EPS. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. On average, equities research analysts anticipate that Revvity Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, October 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. Revvity's dividend payout ratio is presently 11.86%.

Analysts Set New Price Targets

RVTY has been the topic of a number of recent analyst reports. The Goldman Sachs Group decreased their price target on Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Robert W. Baird decreased their price objective on Revvity from $127.00 to $125.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 29th. Raymond James Financial reissued an "outperform" rating and set a $115.00 target price (down previously from $120.00) on shares of Revvity in a research report on Tuesday, July 29th. Evercore ISI dropped their price objective on shares of Revvity from $116.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Finally, UBS Group upgraded Revvity from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $145.00 to $115.00 in a report on Thursday, May 1st. Ten analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $120.07.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.